WO1999023205A1 - Hematopoietic stem cells - Google Patents
Hematopoietic stem cells Download PDFInfo
- Publication number
- WO1999023205A1 WO1999023205A1 PCT/CA1998/001012 CA9801012W WO9923205A1 WO 1999023205 A1 WO1999023205 A1 WO 1999023205A1 CA 9801012 W CA9801012 W CA 9801012W WO 9923205 A1 WO9923205 A1 WO 9923205A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- lin
- stem cells
- human
- cell
- Prior art date
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims abstract description 446
- 210000000130 stem cell Anatomy 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 238000000338 in vitro Methods 0.000 claims abstract description 22
- 230000002950 deficient Effects 0.000 claims abstract description 12
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 5
- 208000016361 genetic disease Diseases 0.000 claims abstract description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 129
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 129
- 210000001185 bone marrow Anatomy 0.000 claims description 35
- 210000004700 fetal blood Anatomy 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 230000003394 haemopoietic effect Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 12
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 101150052863 THY1 gene Proteins 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 9
- 230000011132 hemopoiesis Effects 0.000 claims description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 210000005087 mononuclear cell Anatomy 0.000 claims description 5
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010002965 Aplasia pure red cell Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 3
- 208000027205 Congenital disease Diseases 0.000 claims description 3
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 claims description 3
- 201000004939 Fanconi anemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 3
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 3
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 28
- 238000011579 SCID mouse model Methods 0.000 description 26
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 25
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 25
- 230000002629 repopulating effect Effects 0.000 description 18
- 238000002054 transplantation Methods 0.000 description 17
- 238000011124 ex vivo culture Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000005260 human cell Anatomy 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000012894 fetal calf serum Substances 0.000 description 13
- 230000003021 clonogenic effect Effects 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 8
- 210000000777 hematopoietic system Anatomy 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 230000000925 erythroid effect Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000011476 stem cell transplantation Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 5
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 5
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 102100022749 Aminopeptidase N Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000015872 Gaucher disease Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000013925 CD34 antigen Human genes 0.000 description 2
- 108050003733 CD34 antigen Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000005868 ontogenesis Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101100127892 Caenorhabditis elegans let-60 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940084769 humulin r Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
Definitions
- the present invention relates to human hematopoietic stem cells and to methods of isolating and using such cells in compositions and in methods for the reconstitution of a deficient or missing cell population.
- the present invention also provides a population of human hematopoietic stem cells that can be isolated and genetically altered for introduction in a human patient to correct various genetic disorders.
- CD34 antigen was thought to be the distinguishing feature of stem cells because CD34 is downregulated as stem cells differentiate into more abundant mature cells (4), and CD34 has been used as a basis for isolation of stem cells.
- CD34 does not mark stem cells exclusively, since 1% of bone marrow cells are CD34+ and include clonogenic progenitors that are not able to repopulate the hematopoietic system after transplantation. Other markers such as Thy-1 can be combined with CD34 to positively select for a cell fraction more enriched in stem cells (5, 6, 7).
- the CD34+ cell fraction can be enriched by eliminating cells that express markers that are expressed on non-repopulating cells (e.g.lineage antigens). Nevertheless, all current clinical and experimental protocols utilizing human stem cells, including ex vivo culture, gene therapy and bone marrow transplantation, focus on CD34+ cells.
- Figure 1A shows cell surface expression of CD34 on cord blood cells depleted for lineage markers (Lin-).
- Lin- cells were stained with a class III monoclonal antibody for CD34 (581) conjugated to FITC (Becton
- Diseases may include but are not restricted to congenital disorders, severe combined immunodeficiency, Wiskott-Aldrich syndrome, Fanconi's anemia, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, megakaryoblastic leukemia, hematologic melanomas, lymphoma, multiple myeloma, myelodysplastic syndromes, carcinomas, neuroblastomas, arthritis and neurological genetic diseases (e.g. Gaucher Disease).
- congenital disorders severe combined immunodeficiency, Wiskott-Aldrich syndrome, Fanconi's anemia, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, mega
- CD34-cells that do not express lineage markers exist in human hematopoietic tissues Fig. 1 A.
- the possibility that CD34 protein was produced in the CD34-Lin- cells but not transported to the cell surface was excluded using pe ⁇ neabilized, stained cytospins of purified CD34-Lin- that were further conjugated with fluorescent monoclonal antibodies. This confirmed that no CD34-FITC signal was detected in the CD34-Lin- cells (Fig. IB).
- mice A total of 15 of 35 mice were engrafted following transplantation with CD34-Lin- cells that had been cultured for 4 days in SF or 5% FCS at cell doses below the calculated frequency of CD34-SRC. For example, 13 of 29 mice were engrafted following transplantation of 50,000 to as few as 4,000 cultured CD34-Lin- cells. By contrast, only 1 of 7 mice were engrafted when 100,000 uncultured CD34-Lin- cells were transplanted ( Figure 2). Similarly, a higher proportion of mice (33%) transplanted with cultured CD34-CD38-Lin- cells were engrafted (Figure 7B) compared to mice transplanted with similar doses of uncultured CD34-CD38-Lin- ( Figure 7B).
- CD33+, CD14+, CD15+ and CD13+ cells indicated the differentiation potential of CD38-CD38-Lin- cells to the myeloid lineages (Fig. 8G-H).
- the engraftment pattern of mice transplanted with expanded CD34-CD38-Lin- cells is similar to that observed with unstimulated purified CD34-Lin- cells.
- the presence of human T-cells is a unique feature of CD34-Lin- engraftment, since T-cells have not been detected in mice transplanted with purified CD34+CD38-Lin- cells either before or after ex vivo culture. We had previously found that the CD34+SRC are lost if CD34+CD38-
- the stem cells of the present invention can be identified and isolated from bone marrow, peripheral blood and cord blood.
- the most clinically advantageous source is peripheral blood due to the fact that the procedure for obtaining such is easy and non- invasive. Collection of peripheral blood also has no health effect on the donor. While peripheral blood is the most convenient and least invasive source for use in isolating the stem cells of the present invention, it is understood by those skilled in the art that the bone marrow and cord blood are more ideal as a starting point due to the larger percentage of stem cells present in such.
- Other techniques which may be used to isolate the stem cells of the present invention include immunoseparation where antibodies against specific receptor molecules are used together with immunoaffinity columns to bind cells having the specific target receptor. The targeted cells are then removed from the antibody complex by the use of shear fluid force.
- the cells of the present invention can be used to screen compounds which may affect their proliferation and/or differentiation into other cell types.
- an isolated population of CD34-Lin- cells may be suitably cultured in vitro to which selected growth factors, cytokines, chemicals, peptides and other agents are added individually or in specific combination.
- selected growth factors, cytokines, chemicals, peptides and other agents are added individually or in specific combination.
- One skilled in the art would readily comprehend the conditions and procedures for preparing such a cell culture and the amounts of agent to add for such testing.
- the CD34-Lin- cells may be phenotypically characterized and counted in order to determine the effect of the added agent(s). In this manner, one may establish a simple method for producing a specific cell type for a clinical application.
- the cells of the present invention can be used for understanding the origin of hematopoietic diseases such as leukemia and for clinical procedures such as stem cell transplantation and gene therapy for the treatment of various diseases.
- the stem cell of the present invention is also important for the treatment or prophylaxis against disease or infection, for the reconstitution of deficient or missing cell populations, as for example in cancer patients after myeloablative therapy, and for the treatment of congenital or acquired genetic abnormalities and defects by the introduction of desired genetic infoimation into the patient.
- the CD34-Lin- or CD34- CD38-Lin- stem cells can be utilized for stem cell transplantation in order to reconstitute missing or deficient cell populations.
- Bone marrow transplants are typically done in order to restore hematopoiesis in cancer patients receiving high doses of chemotherapy and/or radiation therapy as well as in leukemia patients and aplastic anemia patients.
- Cord blood has recently been used in order to reconstitute hematopoiesis as an alternative to bone marrow transplants.
- bone marrow transplants there are several disadvantageous with bone marrow transplants as they are highly invasive and require major surgery. One also must find a suitable phenotypically matched donor.
- Peripheral blood transplantation can also be used to isolate and provide back an enriched culture of CD34-Lin- or CD34-CD38-Lin- cells.
- Diseases may include but are not restricted to congenital disorders, severe combined immunodeficiency, Wiskott-Aldrich syndrome, Fanconi's anemia, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, megakaryoblastic leukemia, hematologic melanomas, lymphoma, multiple myeloma, myelodysplastic syndromes, carcinomas, neuroblastomas, arthritis and neurological genetic diseases (e.g. Gaucher Disease).
- congenital disorders severe combined immunodeficiency, Wiskott-Aldrich syndrome, Fanconi's anemia, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, mega
- compositions of the present invention may comprises substantially pure populations of CD34- Lin- human hematopoietic stem cells or CD34-CD38-Lin- human hematopoietic stem cells.
- the compositions may also comprise enriched cultures of CD34- Lin- or CD34-CD38-Lin- cells.
- the compositions of the present invention may additionally comprise cells selected from the group consisting of CD34+ cells, Thy-1 cells, CD4+ cells, CD56+ cells, CD33+ cells, CD9+ cells, CD11+ cells, CD41+ cells, CD45 cells and mixtures thereof.
- the type of composition made depends on the end use. For example, for the treatment of leukemia it is desired to provide a composition comprising substantially homogenous populations of CD34-Lin- or CD34-
- the composition may comprise a mixture of CD34-Lin- or CD34-CD38-Lin- cells together with CD34+ cells.
- compositions substantially enriched populations of cells characterized phenotypically as CD34-Lin- or CD34-CD38-Lin- but which also may be further phenotypically characterized by the presence or absence of other antigenic markers.
- the CD34-Lin- or CD34-CD38-Lin- cells may be used as a method of gene therapy.
- the CD34-Lin- or CD34-CD38-Lin- cells may be isolated and enriched in in vitro culture where a desired genetic sequence can be inserted into the cells prior to their reintroduction into a patient.
- the genetic element introduced can simply be one to correct a defect in the cells themselves or to target a specific recombinant gene sequence to a specific area of the patient.
- diseases which may be treated with genetically altered stem cells of the present invention include but are not restricted to hemophilia A, thalassemia, sickle-cell anemia, SCID and Gaucher's disease.
- CD34-Lin- or CD34-CD38-Lin- cells are isolated from a source and cultured according to the method of the present invention.
- the cell culture is maintained under suitable conditions and the cells are subjected to techniques for the introduction and stable incorporation of a desired genetic sequence into the cells.
- introduction techniques may include transfection (calcium-mediated or microsome-mediated transfection), cell fusion, electroporation, microinjection or infection using recombinant vaccinia or retrovirus vectors.
- the cells which acquire the selected genetic sequence are then screened for, and reintroduced into a patient.
- the identifed cells may be further cultured to allow the cells to enrich and/or further differentiate to another cell type prior to being reintroduced into a patient.
- the cells of the present invention may be trans fected with a selected
- DNA sequence encoding for a therapeutic agent such as an antibiotic, anticancer agents, peptides, cytotoxic compounds and antisense RNA.
- the cells may be transfected with an antigenic or immunogenic product which creates an immune response in a patient and reintroduction. In this manner, such cells would produce a vaccine like effect.
- the cells of the present invention can be used for fetal genetic testing.
- the stem cells may be isolated from samples of peripheral blood taken from a pregnant woman which contain some fetal cells. Isolated fetal cells may be cultured and the stem cells isolated and tested for genetic abnormalities.
- the stem cells of the present invention may be isolated and cultured in vitro and treated with specific factors and/or cytokines in order to produce a specific cell lineage such as immune cells, granulocytic, megakaryocytic, etc. which carry out a specific function.
- a specific cell lineage such as immune cells, granulocytic, megakaryocytic, etc. which carry out a specific function.
- Such specialized cells may be generated in large numbers and transplanted back into patients in order to treat them of a disease such as for example an autoimmune disease or one of the diseases listed supra.
- Example 1 Analysis of CD34-Lin- cells found in human hematopoietic tissue Mononuclear cells were isolated from various human hematopoietic cell sources and stained with monoclonal antibodies for CD2, CD3, CD4, CD7, CD13, CD14, CD15, CD16, CD19, CD20, and glycophorin conjugated to FITC, CD38 conjugated to PE and CD34 conjugated to Cy-5 . Cells gated Rl did not express lineage associated markers (Lin-) and were further analyzed for the expression of CD34 and CD38.
- CD34- cells that do not express lineage markers exist in human hematopoietic tissues
- human cord blood cells were first depleted of mononuclear cells that express 15 different lineage-specific antigens from human cord blood. This Lin- population was 99% pure (data not shown). The Lin- cells were then stained with the most widely used CD34 class III monoclonal antibody conjugated to FITC. Flow cytometric analysis showed two distinct populations of CD34+ and CD34- cells (Fig 1A panel 1). The CD34- cells (gated Rl, Fig. 1A, I) were collected by flow sorting and reanalysis demonstrated their high purity (99%; Fig. 1 A, II).
- cytospins of purified CD34- Lin- cells were permeabilized, stained with CD34 monoclonal antibodies conjugated to FITC and counter stained with DAPI (Fig. IB).
- No CD34-FITC signal was detected in the CD34-Lin- cells.
- the specificity of the procedure was shown by the detection of cell surface and intracellular expression of CD34 on a population of purified CD34+Lin- cells under similar conditions. Background fluorescence was indicated by staining cells with IgG conjugated to FITC as isotype control (Fig. IB).
- CD34+Lin- cells Heterogeneity within human CD34+Lin- cells is well documented and further subdivision for the most primitive cells is typically based on the cell surface markers CD38, c-kit, Thy-1 and HLA-DR. The expression of these markers on both the CD34+Lin- and CD34-Lin- cells was compared (Fig. IC).
- CD34-Lin- cells displayed a bi-modal distribution of CD38, clearly dividing the population into two fractions in contrast to the high proportion of CD34+Lin- cells that express CD38 (Fig. IC).
- Cell surface expression of c-kit was similar between that two populations, while the CD34-Lin- cells are almost exclusively Thy-1- and HLA-DR- (Fig. IC).
- CD34-Lin- population derived from cord blood is a distinct population which differs not only in CD34 expression from primitive CD34+Lin- cells but also in phenotypic heterogeneity based on additional markers associated with stem cells.
- Example 3 Cell Engraftment Purified cell populations at the indicated dose were transplanted by tail vein injection into sublethally irradiated mice (375 cGy using a 137Cs g- irradiator) according to a standard protocol as previously described (16, 17). Mice were sacrificed 8 to 12 weeks post transplant and the bone marrow from the femurs, tibiae and iliac crests of each mouse were flushed into IMDM containing 10% FCS.
- Mouse bone marrow was analyzed using FACS analysis and by southern analysis using genomic DNA extracted by standard protocols in which the level of human cell engraftment was determined by comparing the characteristic 2.7 kb band with those of huma mouse DNA mixtures as controls (limit of detection 0.05% human DNA) (16, 17). The results are shown in Figures 2 and 7.
- Example 4 Determination of Hematopoietic Progenitor Activity of CD34-Lin.
- CD34+CD38-Lin- and CD34-CD38+Lin- Highly purified cells were plated in clonogenic methlycellulose assays and seeded on MS-5 stroma in order to quantitate the CFC and LTC-IC content, respectively.
- Clonogenic capacity of CD34-Lin- cells was extremely low in comparison to CD34+CD38-Lin- cells (250 CFC vs. 8.9 CFC per 800 cells) (Table I).
- CD34-CD38-Lin- cells As many as 10,000 cells needed to be seeded on MS-5 stroma to detect a single LTC-IC within the CD34-Lin- cell fraction, while further purification demonstrated that detection of LTC-IC in the CD34-CD38-Lin- fraction required seeding of at least 2000 cells. By contrast, as few as 10 CD34+CD38-Lin- cells contain an LTC-IC.
- the CD34-CD38+Lin- cells were devoid of LTC-IC activity (limit of detection at 10,000 cells) but contained a much higher capacity to form CFC specifically committed to the erythroid lineage (Table I).
- Example 5 Multilineage Differentiation of Human CD34-Lin- cells in NOD/SCID mice after ex vivo Culture
- a representative mouse was transplanted with 50,000 expanded CD34- Lin- cord blood cells after 2 days of ex-vivo culture in the presence of SF medium supplemented with 5% FCS.
- Mouse bone marrow was extracted 10 weeks after transplant and analyzed by multiparameter flow cytometry (11, 12). The results are shown in Figure 8.
- CD34-Lin- cells were incubated in 50 ml of SF condition consisting of IMDM supplemented with 1% BSA (Stem Cell Technologies), 5 mg/ml of human insulin (Humulin R from Eli Lilly and Co.), 100 mg/ml of human transferrin (Gibco, BRL), 10 mg/ml of low density lipoproteins (Sigma Chemical Co.), 10-4 M Beta-mercaptoethanol and growth factors (GF).
- GF cocktail was used at final concentrations of 300 ng/ml of SCF (Amgen) and Flt- 3 (Immunex), 50 ng/ml of G-CSF (Amgen), 10 ng/ml of IL-3 (Amgen) and IL- 6 (Amgen).
- condition media obtained from a fresh umbilical vein endothelial cell culture in a low percentage of serum ( 10%) and passaged four times, was added in some wells.
- Cells were cultured in flat bottomed suspension wells of 96-well plates (Nunc), incubated for 2 and 4 days at 37oC and 5% C02 and 50 ml of fresh GF cocktail was added to each well every other day.
- Example 6 Effect of ex vivo culture on the number of clonogenic progenitors present in the CD34-Lin-.
- CD34-CD38-Lin- and CD34-CD38+Lin- cell fractions An aliquot of 800 to 2, 500 CD34-Lin-, CD34-CD38-Lin- or CD34-
- Example 7 The effect of liquid culture on the development and potential differentiation of CD34-CD38-Lin- cells
- CD34-CD38-Lin- cells seeded in SF media began to express CD34 which could be enhanced with the addition of serum (Fig. 6).
- HUNEC human umbilical vein endothelial cell
- CD34-Lin- and more highly purified CD34-CD38-Lin- cell fractions were injected into ⁇ OD/SCID mice and the level of human engraftment evaluated after 8 to 10 weeks.
- Purified cell fractions from 44 CB and 3 BM samples cultured for 2 and 4 days in SF, SF supplemented with 5% FCS or 25% HUVEC-CM were transplanted at various doses into 144 recipient ⁇ OD/SCID mice and the level of human cell engraftment was determined (Figure 7B).
- mice A total of 15 of 35 mice were engrafted following transplantation with CD34-Lin- cells that had been cultured for 4 days in SF or 5% FCS at cell doses below the calculated frequency of CD34-SRC. For example, 13 of 29 mice were engrafted following transplantation of 50,000 to as few as 4,000 cultured CD34-Lin- cells. By contrast, only 1 of 7 mice were engrafted when 100,000 uncultured CD34-Lin- cells were transplanted ( Figure 2). Similarly, a higher proportion of mice (33%) transplanted with cultured CD34-CD38-Lin- cells were engrafted (Figure 7B) compared to mice transplanted with similar doses of uncultured CD34-CD38-Lin- ( Figure 7B).
- the bone marrow of engrafted mice was analyzed by multiparameter flow cytometry to determine whether cultured CD34-Lin- repopulating cells possessed the same in vivo proliferative and differentiative capacity as uncultured cells.
- a representative analysis of the bone marrow of a NOD/SCID mouse transplanted with an initial population of 40,000 CD34-Lin- cells after 4 days of culture is shown in Figure 8.
- the bone marrow of this mouse contained 7% human cells as detected by expression of CD45, a human specific pan- leukocyte marker (Fig. 8). Both B and T-lymphoid cells were present in the murine bone marrow as shown by staining for CD 19, CD20 and CD4, CD3 antigens (Fig. 8D-F).
- CD33+, CD14+, CD15+ and CD13+ cells indicated the differentiation potential of CD38-CD38-Lin- cells to the myeloid lineages (Fig. 8G-H).
- the engraftment pattern of mice transplanted with expanded CD34-CD38-Lin- cells is similar to that observed with unstimulated purified CD34-Lin- cells.
- the presence of human T-cells is a unique feature of CD34-Lin- engraftment, since T-cells have not been detected in mice transplanted with purified CD34+CD38-Lin- cells either before or after ex vivo culture.
- CD34+CD38-Lin- or CD34+Lin- cells were cultured for 4 days under the dame serum containing conditions.
- CD34+CD38-Lin- and CD34-Lin- cells were cultured for 4 days under the dame serum containing conditions.
- 3 out of 6 mice were engrafted following transplantation with cultured CD34- Lin- cells ( Figure 9).
- 5,000 and 10,000 CD34+CD38-Lin- cells, containing 10-20 CD34+SRC, cultured under the same conditions were unable to engraft NOD/SCID mice.
- NOD/SCID mice were transplanted with CD34-Lin- or CD34+CD38-Lin- cells purified from the same cord blood sample and cultured in the presence of 5% FCS.
- a southern blot was performed using standard techniques and was hybridized with a human chromosome 17-specific ⁇ -satellite probe.
- CD34-Lin- ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- Phenotype of purified CFC/800 cells Frequency of population LTC-IC
- Phenotype of purified Day Medium Number l ⁇ ?l population
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to human hemotopoietic stem cells characterized as CD34-Lin- and CD34-CD38-Lin- and to methods of isolating and using such cells in compositions and in methods for the reconstitution of a deficient or missing cell population. The present invention also provides a population of human hematopoietic stem cells that can be isolated and genetically altered for introduction in a human patient, to correct various genetic disorders and cultured and further differentiated in vitro to provide a new population of cells.
Description
Hematopoietic Stem Cells
Field of the Invention
The present invention relates to human hematopoietic stem cells and to methods of isolating and using such cells in compositions and in methods for the reconstitution of a deficient or missing cell population. The present invention also provides a population of human hematopoietic stem cells that can be isolated and genetically altered for introduction in a human patient to correct various genetic disorders.
Background of the Invention
The mammalian hematopoietic system consists of a heterogeneous array of cells ranging from large numbers of differentiated cells with defined function to rare pluripotent stem cells with extensive developmental and proliferative potential (1, 2, 3). The defining feature of a stem cell is its ability to repopulate the hematopoietic system of a recipient after transplantation. Stem cells are playing an increasingly important role in clinical and commercial applications, as the role of stem cells in transplantation widens. Identification and purification of stem cells is essential both to determine the cellular and molecular factors that govern stem cell development and for the application of clinical procedures including stem cell transplantation and gene therapy. Cell surface expression of the CD34 antigen was thought to be the distinguishing feature of stem cells because CD34 is downregulated as stem cells differentiate into more abundant mature cells (4), and CD34 has been used as a basis for isolation of stem cells. CD34, however, does not mark stem cells exclusively, since 1% of bone marrow cells are CD34+ and include clonogenic progenitors that are not able to repopulate the hematopoietic system after transplantation. Other markers such as Thy-1 can be combined with CD34 to positively select for a cell fraction more enriched in stem cells (5, 6, 7).
Conversely, the CD34+ cell fraction can be enriched by eliminating cells that express markers that are expressed on non-repopulating cells (e.g.lineage antigens). Nevertheless, all current clinical and experimental protocols utilizing human stem cells, including ex vivo culture, gene therapy and bone marrow transplantation, focus on CD34+ cells.
There have been reports (8, 9, 10) of murine CD34- hematopoietic stem cells which are capable of long term repopulation. For human hematopoietic stem cells, however, the CD34+ antigen has been regarded as a stem cell marker without exception.
Summary of the Invention
The present inventors have identified and isolated a population of human hematopoietic stem cells which do not express CD34 (CD34-), CD38 (CD38-) or lineage specific markers (Lin-) and which are able to generate, by proliferation and differentiation, multiple lineages of the human hematopoietic system, as evidenced by their ability to produce multilineage human hematopoietic engraftment of immune-deficient NOD/SCID mice after transplantation. Moreover, the repopulative capacity and the differentiative capacity of the CD34-CD38-Lin- cells can be stimulated by in vitro culture of these cells.
According to an object of the present invention there is provided a substantially homogeneous population of human hematopoietic stem cells which are CD34-Lin-.
According to another object of the present invention there is provided a substantially homogeneous population of human hematopoietic stem cells which are CD34-CD38-Lin-.
According to another object of the present invention there is provided a therapeutic composition comprising an effective amount of CD34- Lin- human hematopoietic stem cells and a pharmaceutically acceptable carrier.
According to another object of the present invention there is provided a therapeutic composition comprising an effective amount of CD34-CD38-Lin- human hematopoietic stem cells and a pharmaceutically acceptable carrier.
According to yet a further object of the present invention there is provided a method for obtaining a substantially enriched population of CD34- Lin- human hematopoietic cells comprising the steps of:
- removing mononuclear cells expressing some lineage-specific antigens from a sample of hematopoietic cells;
- combining the resultant hematopoietic cells with labeled antibodies to which bind specifically to CD34+; and
- isolating the unbound CD34-Lin- cells.
According to still another object of the present invention there is provided a method for reconstituting hematopoiesis in an immunocompromised subject, the method comprising administering to a subject a composition comprising an enriched population of CD34- Lin- stem cells.
According to a further object of the present invention there is provided a method for introducing CD34-Lin- stem cells in a mammal, said method comprising the steps of:
- providing an enriched population of CD34-Lin- stem cells; and - introducing said stem cells into said mammal.
According to another object of the present invention there is provided a method of treating a hematopoietic disorder in a subject, comprising:
- providing an enriched population of human CD34-CD38-Lin- stem cells; administering said stem cells to the subject in need of treatment.
According to another object of the present invention there is provided a method for the production of CD34+ stem cells, said method comprising:
- providing an enriched population of human CD34-CD38-Lin- stem cells;
- culturing said stem cells in vitro under suitable conditions for a time sufficient to allow said cells to differentiate into CD34+ cells; and
- isolating CD34+ stem cells.
According to still a further object of the present invention there is provided a method for expanding a population of CD34-Lin- stem cells, said method comprising the steps of:
- isolating CD34-Lin- stem cells from suitable hematopoietic source;
- culturing said isolated cells in vitro for a time sufficient and under culture conditions to result in the expansion of said cells.
Brief Description of the Drawings
Certain embodiments of the invention are described, reference being made to the accompanying drawings, wherein: Figure 1A shows cell surface expression of CD34 on cord blood cells depleted for lineage markers (Lin-). (Panel I) Lin- cells were stained with a class III monoclonal antibody for CD34 (581) conjugated to FITC (Becton
Dickinson, BD). Cells residing in Rl were considered CD34 negative (CD34-).
(Panel II) CD34- cells were purified using standard cell sorting techniques and re-analyzed using the same CD34-581 antibody. (Panel III and Panel IN)
Purified Rl cells were stained and re-analyzed using a class I monoclonal antibody for CD34 (Immun-133) (Coulter) and a class II monoclonal antibody for CD34 (Q-Bend-10) (Becton Dickinson, BD).
Figure IB shows cell populations immunostained for CD34 expression. Representative cells are shown from a total of 25-75 cells examined for each treatment (n=2).
Figure 1C shows a comparison of cell surface markers between CD34-
Lin- versus CD34+Lin- cord blood cells.
Figure 2 shows level of human cell engraftment in NOD/SCID mice transplanted with highly purified CD34-Lin- cells at various indicated doses. Figure 3 shows the multilineage differentiation of human CD34-Lin- cells in NOD/SCID mice. Bone marrow from a highly engrafted mouse transplanted with 120,000 CD34-Lin- cord blood cells was stained with various human-specific monoclonal antibodies and analyzed by flow cytometry. Approximately 106 mononuclear cells collected from mouse bone marrow were prepared for multilineage analysis (12). (A) Cells with medium to high forward scatter (region Rl) were gated and further analyzed. (B) Histogram of CD45 (pan-leukocyte marker) expression indicating that 2.5% of the cells present in the murine bone marrow are human, gated R2. All further lineage markers were examined on cells within gate R2 (CD45+). (C) Isotype control for non-specific IgG staining of PE and FITC fluorescence. (D) Expression of myeloid marker CD33 and granulocyte marker CD15; (E) pan-B cell markers CD19 and CD20; (F) CD38 and the immature hematopoietic marker CD34; (G and H) T-cell markers CD2, CD3, CD4 and CD8.
Figures 4A and 4B show frequency analyses of CD34-Lin- cells and CD34-CD38-Lin- cells found in human hematopoietic tissue. Figure 4A: Column I: Fetal liver collected from 8 week old human fetus, n=3; Column II: Fetal blood aspirated from 19 week old fetus, n=l; Column III: Cord blood collected from placenta at time of birth, n=3. Figure 4B: Column I: Normal Adult Bone marrow, n=2; Column II: Bone marrow from a normal adult donor after 5 days of G-CSF administration, n=2; Column III: Peripheral blood collected from a normal adult donor after 5 days of G-CSF administration, n=2. Figure 5 shows the percentage of input cells after in vitro culture of
CD34-Lin- cells. Purified cells were counted and seeded (250-2000) in wells containing serum free media (SF) (solid bars) or SF supplemented with 25% HUVEC- conditioned media ( shaded bars). Cells were counted each day and the percentage of input cells was calculated ( n=3).
Figure 6 shows an analysis of CD34 and CD38 expression of highly purified cell populations after in vitro culture. A representative experiment (n=4) of CD34 and CD38 cell surface expression performed on initially purified CD34-CD38-Lin- cells, and purified cells after 2 and 4 days of culture in SF, SF supplemented with 5% FCS or 25% HUNEC-CM. The entire contents of individual wells was collected at 2 and 4 days (5000-10, 000 cells), stained with monoclonal antibodies CD34 and CD38 directly conjugated to FITC and PE respectively (Becton Dickinson, BD). Stained populations were then washed and analyzed using standard flow cytometric techniques, followed by the display of histograms using the Cell Quest software program (BD).
Figure 7A shows levels of engraftment of non expanded CD34-CD38- Lin- or CD34-CD38+Lin- cell fractions in ΝOD/SCID mice.
Figure 7B shows the capacity of CD34-Lin-, CD34-CD38+Lin- and CD34-CD38-Lin- cell fractions to engraft ΝOD/SCID after ex vivo culture. (A) The level of human cell engraftment is the BM of 136 mice transplanted with either CD34-Lin-, CD34-CD38-Lin- or CD34-CD38+Lin- cell fractions seeded at the indicated cell doses after day 2 or 4 of ex vivo culture from 43 CB and 3BM samples.
Figures 8 A to 8H show the multilineage differentiation of human CD34- Lin- cells in ΝOD/SCID mice after ex vivo culture represented in histograms. Figure 8A: Histogram of CD45 (human-specific pan-leukocyte marker) expression indicating that 7% of the cells present in the murine bone marrow are human. Figure 8B: Forward and Side scatter of the CD45 human cells. Subsequent analysis of lineage markers was done on CD45+ cells within gate Rl (lymphoid and blast cells) or R2 (myeloid cells) gates. Figure 8C: Analysis for the presence of immature cells using the CD34 and CD38 markers. Figure 8D: Analysis for the presence of human B cell lineage cells using CD 19 and CD20 markers. Figures 8E to 8F: Analysis for the presence of human T lymphocytes using the panel of T cell markers: CD2, CD3, CD4 and CD8.
Figures 8G to 8H: Analysis for the presence of myeloid cells using CD33, CD14, CD15 and CD13 markers.
Figure 9 shows DNA analysis of NOD/SCID mice transplanted with CD34-Lin- or CD34+CD38-Lin- cells purified from the same cord blood sample and cultured in the presence of 5% FCS. The southern blot was hybridized with a human chromosome 17-specific α-satellite probe.
Detailed Description of the Invention
The identification of the CD34-Lin- and CD34-CD38-Lin- human hematopoietic stem cell has important implications for understanding the origin of hematopoietic diseases such as leukemia and for clinical procedures such as stem cell transplantation and gene therapy for the treatment of various diseases. The stem cell of the present invention is also important for the treatment or prophylaxis against disease or infection, for the reconstitution of deficient or missing cell populations, as for example in cancer patients after myeloablative therapy, and for the treatment of congenital or acquired genetic abnormalities and defects by the introduction of desired genetic information into the patient. The CD34-Lin- and CD34-CD38-Lin- human hematopoietic stem cells of the present invention can be isolated using standard techniques of cell sorting in order to rapidly identify and isolate the cells so that they may be isolated ex vivo and cultured in vitro to provide an expanded population of the cells for use as a therapeutic composition for humans requiring such. Such ex vivo cultured cells may be genetically manipulated as required prior to being reintroduced back into a patient. In accordance with one embodiment, the invention provides a substantially homogeneous population of human hematopoietic stem cells which are characterized as CD34-Lin- and CD34-CD38-Lin-.
In accordance with a further embodiment, the invention provides a method for preparing a substantially homogeneous population of human hematopoietic stem cells which are CD34-Lin- and CD34-CD38-Lin-.
In accordance with a further embodiment, the invention provides a therapeutic composition comprising CD34-CD38-Lin- human hematopoietic stem cells. The invention also provides a therapeutic composition comprising CD34-CD38-Lin- human hematopoietic stem cells. Such compositions can be used to treat hematopoietic disorders such as malignancies (i.e. leukemia), immune disorders and diseases resulting from a failure or a dysfunction of normal blood cell production or maturation. Diseases may include but are not restricted to congenital disorders, severe combined immunodeficiency, Wiskott-Aldrich syndrome, Fanconi's anemia, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, megakaryoblastic leukemia, hematologic melanomas, lymphoma, multiple myeloma, myelodysplastic syndromes, carcinomas, neuroblastomas, arthritis and neurological genetic diseases (e.g. Gaucher Disease).
The novel stem cells of the present invention may be used in various clinical procedures such as stem cell transplantation for the reconstitution of a deficient or a missing cell population, therapy, gene therapy and for combating infection.
In accordance with another aspect of the invention there is provided a method for the treatment of hematopoietic disorders such as leukemia comprising the use of human hematopoietic cells characterized as CD34-Lin- and CD34-CD38-Lin-.
In accordance with another aspect of the present invention is a method for the ex vivo generation of human hematopoietic cells using CD34-Lin- cells and/or CD34-CD38-Lin- cells.
In accordance with another aspect of the present invention is a gene therapy method for providing genetically altered human hematopoietic cells characterized as CD34-Lin- or CD34-CD38-Lin- to a patient.
In accordance with another aspect of the present invention is a method for reconstituting deficient or missing human hematopoietic cell populations comprising the use of CD34-Lin- cells or CD34-CD38-Lin- cells.
In accordance with another aspect of the present invention is a method for transplanting human hematopoietic cell populations to a patient comprising the use of CD34-Lin- and CD34-CD38-Lin- cells. In accordance with another aspect of the present invention is a method for combatting infection in a patient comprising administering an effective amount of human hematopoietic cells characterized as CD34-Lin- or CD34- CD38-Lin-.
In accordance with yet a further aspect of the present invention there is provided a method utilizing human hematopoietic cells characterized as CD34- Lin- or CD34-CD38-Lin- for the production of CD34+ human hematopoietic cells.
In accordance with a further aspect of the present invention is a method for increasing the repopulating capacity of human hematopoietic cells characterized as CD34-Lin- or CD34-CD38-Lin- by culturing such cells in vitro for several days.
In accordance with a further aspect of the present invention is a method for screening candidate compounds affecting proliferation or differentiation of stem cells characterized as CD34-Lin- and CD34-CD38-Lin-.
Characterization of Hematopoietic Stem Cells
It was determined, using CD34 class III fluorescent monoclonal antibodies, that CD34- cells that do not express lineage markers exist in human hematopoietic tissues (Fig. 1 A). The possibility that CD34 protein was
produced in the CD34-Lin- cells but not transported to the cell surface was excluded using peπneabilized, stained cytospins of purified CD34-Lin- that were further conjugated with fluorescent monoclonal antibodies. This confirmed that no CD34-FITC signal was detected in the CD34-Lin- cells (Fig. IB).
Heterogeneity within human CD34+Lin- cells is well documented and further subdivision for the most primitive cells is typically based on the cell surface markers CD38, c-kit, Thy-1 and HLA-DR. The expression of these markers on both the CD34+Lin- and CD34-Lin- cells was compared (Fig. 1C). CD34-Lin- cells displayed a bi-modal distribution of CD38, clearly dividing the population into two fractions, in contrast to the high proportion of CD34+Lin- cells that express CD38 (Fig. 1C). Cell surface expression of c-kit was similar between the two populations, while CD34-Lin- cells were almost exclusively Thy-1- and HLA-DR- (Fig. 1C). Both the absence of HLA-DR expression and the presence of Thy- 1 have been proposed as defining more primitive subfractions within the CD34+Lin- population. Therefore, the CD34-Lin- population derived from cord blood is a distinct population which differs from primitive CD34+Lin- cells not only in CD34 expression but also in phenotypic heterogeneity based on additional stem-cell associated markers. Using clonogenic methylcellulose assays, the hematopoietic progenitor activity of CD34-Lin-, CD34-CD38-Lin- and CD34-CD38+Lin- cells was determined by comparing their CFC and LTC-IC content. The clonogenic capacity of CD34-Lin- cells was extremely low in comparison to that of CD34+CD38-Lin- cells (Table I). As many as 10,000 cells needed to be seeded on MS-5 stroma to detect a single LTC-IC within the CD34-Lin- cell fraction, while further purification demonstrated that detection of LTC-IC in the CD34- CD38-Lin- fraction required seeding of at least 2000 cells. By contrast, as few as 10 CD34+CD38-Lin- cells contain an LTC-IC. The CD34-CD38+Lin- cells were devoid of LTC-IC activity (limit of detection at 10,000 cells) but
contained a much higher capacity to form CFC (colony-forming cells) specifically committed to the erythroid lineage (Table I). The low efficiency of production of myeloid and erythroid committed progenitors, as well as the more primitive LTC-IC, were similar to observations made with murine CD34-Lin- cells in the same assay systems and suggested that functional similarities may exist between the CD34-Lin- cells from these two species.
The only conclusive method for detecting stem cells is to determine their ability to repopulate recipient hosts. The repopulation capacity of primitive human cells can be assayed by their ability to initiate multilineage human engraftment in immune-deficient NOD/SCID mice. Based on cell purification and gene marking, cells capable of repopulating NOD/SCID mice (termed the SCID-Repopulating Cell, SRC) were established as distinct from, and more primitive than, the majority of progenitors detected in in vitro assays. CD34+CD38-Lin- cells, and not CD34+CD38+Lin- cells, gave rise to multilineage engraftment. Transplantation of as many as 106 CD34-Lin+ cells did not give engraftment. To determine whether highly purified CD34-Lin- cells had SRC activity, and to determine the frequency of any repopulating cells, CD34-Lin- cells were transplanted at varying cell doses into NOD/SCID mice using standard protocols, and bone marrow was analyzed for the presence of human cells after 8-12 weeks. The level of human cell engraftment in 23
NOD/SCID mice was quantitated by FACS and DNA analysis for the presence of human cells and results are summarized in Fig. 2. A large proportion of transplanted mice were engrafted with human cells, indicating that CD34-Lin- cells were able to repopulate NOD/SCID mice. This cell was designated the CD34NEG-SCID Repopulating Cell (CD34NEG-SRC). The frequency was 1 CD34NEG-SRC in 125,000 CD34-Lin- cells. The differentiative and proliferative capacity of the CD34NEG-SRC cell was assessed by flow cytometric analysis. A representative engrafted NOD/SCID mouse 10 weeks after the transplant of 120,000 CD34-Lin- cells is shown in Fig. 3. Cells with
medium to high forward scatter (region Rl, Fig. 3 A) were gated and further analyzed, based on CD45 expression, a human specific pan-leukocyte marker (Fig. 3B). The isotype control is shown in Fig. 3C. The bone marrow of this mouse contained 2.5% CD45+ human cells (Fig. 3B), or at least 106 total human cells indicating that the CD34-Lin- cells have extensive proliferative capacity. Human granulocytes (CD 15+) were present among myeloid cells (CD33+) (Fig. 3D). Human B-lymphoid cells were also present in the murine bone marrow as shown by staining for CD 19 and CD20 (Fig. 3E). Interestingly, human T-cells expressing both CD2 and CD3 (Fig. 3G), along with CD4 and CD8 positive cells (Fig. 3H), were also identified. NOD/SCID mice transplanted with highly purified primitive CD34+CD38-Lin- cells never gave rise to engraftment containing T-cells demonstrating the unique in vivo repopulation behavior of the CD34-Lin- cells. In addition to multilineage engraftment, immature CD34+ and CD34+CD38- cells were detected (Fig. 3F). It was concluded that human CD34-Lin- cells have the ability to repopulate
NOD/SCID mice and differentiate in vivo into multiple lineages of myeloid and lymphoid cells. The production of CD34+CD38- and CD34+CD38+ cells in vivo suggests that CD34-Lin- cells are developmentally earlier than CD34+ cells in the hierarchy of human hematopoiesis. There is evidence that the frequency of primitive cells changes during ontogeny with the highest proportions seen in the fetus. A variety of fetal, neonatal, and adult sources of human hematopoietic tissue were analyzed in an attempt to identify and quantify the CD34-Lin- population. The results indicate (Fig. 4A,4B) that CD34-Lin- cells are produced early in human ontogeny and can persist throughout adult life and that the mechanisms that operate during the mobilization of CD34+ cells by G-CSF also affect CD34-Lin- cells.
This data provides the first identification of a novel human hematopoietic stem cell that does not express CD34 or lineage-specific markers. As determined by all available monoclonal antibodies, this population
is not only distinct by the absence of CD34, but also by the lack of HLA-DR and Thy-1 markers. In addition to these phenotypic differences, several lines of evidence functionally distinguish these two stem cell populations. While the CD34-Lin- cells have limited hematopoietic activity in vitro, CD34+CD38-Lin- cells are highly clonogenic based on their ability to produce CFC and LTC-IC. Although both stem cell fractions are capable of repopulation, the presence of T-cells within the multilineage engraftment is a unique characteristic of CD34- Lin- transplantation; human T cells have not been detected in mice transplanted with CD34+CD38-Lin- cells (n=25). It is unlikely, therefore, that NOD/SCID repopulation was derived from contamination of CD34-Lin- cells by
CD34+CD38-Lin- cells. Furthermore, based on LTC-IC frequency, a minimum of 1 LTC-IC resides within 10 highly purified CD34+CD38-Lin- cells. In contrast to flow cytometry, by which it has been determined that the CD34-Lin- population is 99% (or in some cases 100%) pure, the LTC-IC assay allows detection of a smaller number of contaminating CD34+CD38-Lin- cells. Using this assay, only a single LTC-IC could be detected in as many as 10 000 CD34- Lin- cells. If this LTC-IC activity came from a CD34+CD38-Lin- cell, a maximum of 10 CD34+CD38-Lin- cells could be contained in the CD34-Lin- purified fraction (0.1% contamination). In addition, repopulated mice have not been observed when only 10 CD34+CD38-Lin- cells were transplanted (12). Since the frequency of SRC derived from CD34-Lin- cells is 1 in 125 000, a maximum of 125 CD34+CD38-Lin- cells could have been transplanted, again less than the number needed to repopulate CD34+CD38- cells.
The in vivo differentiation of human CD34-Lin- cells into CD34+ and lineage positive cells after murine engraftment suggests that CD34-Lin- cells preceed CD34+ cells in the hierarchy of human hematopoiesis.
It is also possible that the CD34-Lin- cells upon further phenotypic evaluation may contain certain subpopulations of cells with have further different phenotypic antigenic expression. It is also possible that CD34-Lin-
cells have further phenotypic antigenic expression themselves that will further help to isolate these new class of stem cells in a more efficient and rapid manner.
The identification of these novel repopulating cells, termed CD34neg- SCID repopulating cells (CD34neg-SRC), provides an opportunity to examine the differentiation and proliferation potential of these cells and to establish their relationship to other cells within the human stem cell hierarchy. These CD34neg- SRC are found within both the CD34-Lin- cell fraction and the CD34-CD38- Lin- fraction. CD38+ cells identified within the CD34-Lin- fraction do not have repopulation potential.
Many studies based on ex vivo culture have demonstrated that there is heterogeneity within the CD34+ cell fraction. Subfractionation of the CD34+ cells on the basis of Thy 1, CD38, and HLA-DR expression together with in vitro clonogenic and LTC-IC assays have demonstrated the progenitor-progeny relationship of the various cell types that make up the stem cell hierarchy (4, 14). The availability of the SRC assay to detect even earlier cell types has added more information about the organization of cells within this hierarchy (14). Moreover, it was demonstrated that the SRC (derived from CD34+CD38- cells) can be expanded for 4 days in serum-free cultures without inducing their differentiation. However, all SRC are lost within an additional 4 days of culture concommitant with the appearance of more differentiated CD38+ cells (11). At the same time, both colony-forming cells (CFC) and long-term culture initiating cells (LTC-IC) could be greatly expanded during 8 days of culture, demonstrating that the majority of the SRC are a distinct population (11), but may be closely related to ELTC-IC (18). Thus, in vitro culture systems can be used to identify very fine transitions in the developmental program by combining both flow cytometry and functional CFC, LTC-IC and SRC assays. It is now demonstrated that ex vivo culture of CD34-Lin- cells can induce the appearance of CD34+ cells and can increase the proportion of CD34-Lin- cells
that have SRC activity. These studies provide new insight into the developmental program of human hematopoietic stem cells.
Earlier studies demonstrated that the CD34-Lin- cell fraction expressed a bimodal distribution of CD38, allowing for further purification into CD38- and CD38+ subpopulations (12). To determine whether the CD34-Lin-, CD34- CD38-Lin-, and CD34-CD38+Lin- cells could be induced to proliferate and/or differentiate, these cells were cultured in defined serum-free (SF) conditions that have been previously shown to support expansion of Lin34+38- cells and maintenance and modest increase of POS CD34 POS-SRC (11, 17). Cells were plated in methly cellulose assays at day 0, and after day 4 of liquid culture, (Table II) to determine the effect of cytokine stimulation on the clonogenic progenitors present in CD34-Lin-, CD34-CD38-Lin- and CD34-CD38+Lin- cell fractions. Both the CD34-Lin- and more purified CD34-CD38-Lin- cells have a low plating efficiency (PE), 1 in 89 and 1 in 297 CFC respectively, whereas a higher PE of CD34-CD38+Lin- cells (1 in 10.4 cells) was seen. Interestingly, the clonogenic capacity of the CD34-CD38+Lin- cells was restricted to the erythroid lineage. After 4 days of culture in SF media, or SF media supplemented with the addition of 25% conditioned medium obtained from primary human umbilical vein endothelial cells (HUNEC-CM), the PE of all the sub-populations examined had decreased, whereas the addition of 5% of FCS increased the clonogenicity of CD34-Lin- cells and, to a greater extent, CD34-CD38+Lin- cells (Table II). This difference in clonogenicity may reflect heterogenity within CD34-Lin- cells and demonstrates that the CD38+ subfraction is already committed to the erythroid lineage, suggesting that the CD34neg-SRC resides in the CD34-CD38-Lin- subfraction.
To determine whether the CD34-CD38-Lin- cells could be stimulated to proliferate, changes in cell number were recorded between day 0 and 4 of culture with SF or 25% HUVEC-CM (Fig. 5). The total number of cells decreased by 2 fold at day 4 in SF media. Supplementation of 5% fetal calf
serum (FCS) showed no increase in the viability of these cells (data not shown). However, the addition of HUNEC-CM to SF media maintained or slightly increased the total cellularity (Fig.5). These results demonstrate that culture conditions that are optimal for CD34+CD38-Lin- cells (11) are unable to support CD34-CD38-Lin- cells, while soluble components present in primary HUNEC-CM seem to permit their survival.
The effect of culture on the differentiatiation program of CD34-CD38- Lin- cells, from individual wells was analyzed by flow cytometry after 2 and 4 days of culture in various conditions (Fig. 6). Surprisingly, CD34-CD38-Lin- cells seeded in SF media began expression of CD34, which could be enhanced with the addition of 5% serum (Fig. 6). In contrast, the majority of cells obtained after 2 or 4 days of culture in the presence of 25% HUVEC conditioned medium still maintained the original CD34-CD38-Lin- phenotype. The stimulation of CD34-CD38-Lin- cells to differentiate and produce CD34+CD38- cells suggests that CD34-CD38- cells precede the CD34+CD38- population in the hierarchy of human hematopoiesis. Moreover, these results indicate that the CD34-CD38-Lin- cells respond to signals present in SF or 5% serum conditions and that HUNEC-CM can inhibit this stimulation.
To confirm which fraction contained CD34neg-SRC cells, both CD34- CD38-Lin- and CD34-CD38+Lin- cells were transplanted into ΝOD/SCID mice. Transplantation with as few as 10,000 or 4,000 CD34-CD38-Lin- cells, derived from cord blood or bone marrow respectively, resulted in engraftment (Fig. 7A), whereas as many as 180,000 CD34-CD38+Lin- cells were incapable of repopulation (Fig 7 A). These data indicate that the CD34neg-SRC cells present in the CD34-Lin- fraction are restricted to the CD38- subtraction. However, since an entire cord blood sample contains only 1 or 2 CD34neg- SRC (e.g. frequency is 1 CD34neg-SRC in 125,000 CD34-Lin- cells and one cord blood sample contains up to 250,000 CD34-Lin- cells), the losses
associated with subselecting based on CD38 expression resulted in only 9% of samples which repopulated NOD/SCID mice.
To evaluate the repopulating activity of CD34-Lin- and more highly purified CD34-CD38-Lin- cell fractions after ex vivo culture, cultured cells were injected into NOD/SCID mice and the level of human engraftment evaluated after 8 to 10 weeks. Purified cell fractions from 44 CB and 3 BM samples cultured for 2 and 4 days in SF, SF supplemented with 5% FCS or 25% HUNEC-CM were transplanted at various doses into 144 recipient ΝOD/SCID mice and the level of human cell engraftment was determined (Figure 7B). A total of 15 of 35 mice were engrafted following transplantation with CD34-Lin- cells that had been cultured for 4 days in SF or 5% FCS at cell doses below the calculated frequency of CD34-SRC. For example, 13 of 29 mice were engrafted following transplantation of 50,000 to as few as 4,000 cultured CD34-Lin- cells. By contrast, only 1 of 7 mice were engrafted when 100,000 uncultured CD34-Lin- cells were transplanted (Figure 2). Similarly, a higher proportion of mice (33%) transplanted with cultured CD34-CD38-Lin- cells were engrafted (Figure 7B) compared to mice transplanted with similar doses of uncultured CD34-CD38-Lin- (Figure 7B). Quantitative analysis using Poisson statistics indicated a frequency of 1 CD-SRC in 38,000 cultured CD34- CD38-Lin- cells (range 1/22,000 to 1/71,000). It was not possible to calculate the frequency of CD34-SRC in uncultured CD34-CD38-Lin- cells (Figure 7 A) because there was infrequent engraftment despite injection of as many as 50,000 cells. This result indicates that the actual stem cell frequency of freshly isolated cells must be much lower compared to cultured cells. The human lineage distribution in mice transplanted with expanded CD34-Lin- and CD34- CD38-Lin- cells is similar to that with unstimulated purified CD34-Lin- cells (Figure 8). In addition, the inability of cultured CD34-CD38+Lin- cells to engraft mice confirms the absense of repopulating cells within this fraction. It
was evident that culture conditions, especially HUVEC-CM, induce an increase in the number of CD34-SRC in the absence of cell proliferation.
The bone marrow of engrafted mice was analyzed by multiparameter flow cytometry to determine whether cultured CD34-Lin- repopulating cells possessed the same in vivo proliferative and differentiative capacity as uncultured cells. A representative analysis of the bone marrow of a NOD/SCID mouse transplanted with an initial population of 40,000 CD34-Lin- cells after 4 days of culture is shown in Figure 8. The bone marrow of this mouse contained 7% human cells as detected by expression of CD45, a human specific pan- leukocyte marker (Fig. 8). Both B and T-lymphoid cells were present in the murine bone marrow as shown by staining for CD 19, CD20 and CD4, CD3 antigens (Fig. 8D-F). The presence of CD33+, CD14+, CD15+ and CD13+ cells indicated the differentiation potential of CD38-CD38-Lin- cells to the myeloid lineages (Fig. 8G-H). The engraftment pattern of mice transplanted with expanded CD34-CD38-Lin- cells is similar to that observed with unstimulated purified CD34-Lin- cells. The presence of human T-cells is a unique feature of CD34-Lin- engraftment, since T-cells have not been detected in mice transplanted with purified CD34+CD38-Lin- cells either before or after ex vivo culture. We had previously found that the CD34+SRC are lost if CD34+CD38-
Lin- or CD34+Lin- cells are cultured in the presence of serum suggesting that the CD34-SRC are biologically distinct from CD34+SRC. To test this directly, CD34+CD38-Lin- and CD34-Lin- cells from the same human CB sample were cultured for 4 days under the dame serum containing conditions. In a representative experiment, 3 out of 6 mice were engrafted following transplantation with cultured CD34-Lin- cells (Figure 9). In contrast, 5,000 and 10,000 CD34+CD38-Lin- cells, containing 10-20 CD34+SRC, cultured under the same conditions were unable to engraft NOD/SCID mice. These results provide independent confirmation that the repopulating cells derived from the
CD34-Lin- subfraction are biologically distinct from those derived from CD34+CD38-Lin- cells.
It is believed that the repopulating cells of the human hematopoietic system are the CD34-CD38-Lin- sub-population and short term ex vivo culture of this fraction has been observed to increase the proportion of repopulating cells. The ability of CD34-CD38-Lin- cells to produce CD34+CD38- cells in vitro and in vivo demonstrates the developmental capacity of these cells and further suggests that this population of cells is more primitive than the CD34 positive fraction. In addition, conditions evaluated here provide the foundation for future gene transfer and ex-vivo expansion of this novel population and for the identification of factors that stimulate their proliferation and differentiation.
Furthermore, the knowledge that CD34-Lin- cells exist and can repopulate the human hematopoietic system provides a novel therapeutic composition and a method for the treatment of hematopoietic disorders. In particular, the composition and method can be used to treat hematopoietic disorders such as leukemia and for several clinical procedures such as stem cell transplantation, therapy, for combatting infection and for cell reconstitution. These cells can also be used to generate CD34+ cells and possibly other cell types. The new class of stem cells of the present invention provide a new method of treatment for various disorders that is very advantageous. From a small sample of bone marrow, peripheral blood or cord blood, the CD34-Lin- cells can be isolated, maintained in culture, enriched and expanded and stored for later use or further stimulated in culture to differentiate and provide other sources of cell types.
It is understood by those skilled in the art that the stem cells of the present invention can be identified and isolated from bone marrow, peripheral blood and cord blood. The most clinically advantageous source is peripheral blood due to the fact that the procedure for obtaining such is easy and non-
invasive. Collection of peripheral blood also has no health effect on the donor. While peripheral blood is the most convenient and least invasive source for use in isolating the stem cells of the present invention, it is understood by those skilled in the art that the bone marrow and cord blood are more ideal as a starting point due to the larger percentage of stem cells present in such.
The stem cells of the present invention can be isolated using standard techniques .known in the art to identify classes of cells and to select subsets of cells of the hematopoietic systems. One such technique is flow cytometry. A flow cytometer can identify different cells by measuring the light they scatter or the fluorescence they emit as they flow through a laser beam. This it can sort out cells of a particular type from a mixture. A fluorescence activated cell sorter or FACS, can select one cells from thousands of other cells. FACS utilizes a multicolour flow cytometer to detect and separate cells bound with fluorescent conjugated antibodies to the specific antigens that identify the development stage or lineage stage of the cells of the hematopoietic system. Detectable fluorescent signals are generating by hitting the cells with a laser beam as they pass through a flow sheath. A nonfluourescent forward scatter signal is used to represent volume and a side scatter signal detects cellular texture and granularity. The colour signals of the fluorochromes used to conjugate with the antibodies detect the cell specific antigens. FACS analysis can analyze two or more colours simultaneously and generate data which is inputted into a computer program to generate colour plots, histograms and perform statistical analysis.
The stem cells of the present invention can also be isolated using a method of negative selection by depletion of lineage positive cells. In this technique, the undesired cells are selected for and depleted leaving behind the desired cells.
Other techniques which may be used to isolate the stem cells of the present invention include immunoseparation where antibodies against specific
receptor molecules are used together with immunoaffinity columns to bind cells having the specific target receptor. The targeted cells are then removed from the antibody complex by the use of shear fluid force.
The cells of the present invention can be used to screen compounds which may affect their proliferation and/or differentiation into other cell types. For example, an isolated population of CD34-Lin- cells may be suitably cultured in vitro to which selected growth factors, cytokines, chemicals, peptides and other agents are added individually or in specific combination. One skilled in the art would readily comprehend the conditions and procedures for preparing such a cell culture and the amounts of agent to add for such testing. After a period of time the CD34-Lin- cells may be phenotypically characterized and counted in order to determine the effect of the added agent(s). In this manner, one may establish a simple method for producing a specific cell type for a clinical application. The cells of the present invention can be used for understanding the origin of hematopoietic diseases such as leukemia and for clinical procedures such as stem cell transplantation and gene therapy for the treatment of various diseases. The stem cell of the present invention is also important for the treatment or prophylaxis against disease or infection, for the reconstitution of deficient or missing cell populations, as for example in cancer patients after myeloablative therapy, and for the treatment of congenital or acquired genetic abnormalities and defects by the introduction of desired genetic infoimation into the patient.
In an embodiment of the present invention, the CD34-Lin- or CD34- CD38-Lin- stem cells can be utilized for stem cell transplantation in order to reconstitute missing or deficient cell populations. Bone marrow transplants are typically done in order to restore hematopoiesis in cancer patients receiving high doses of chemotherapy and/or radiation therapy as well as in leukemia patients and aplastic anemia patients. Cord blood has recently been used in
order to reconstitute hematopoiesis as an alternative to bone marrow transplants. However, there are several disadvantageous with bone marrow transplants as they are highly invasive and require major surgery. One also must find a suitable phenotypically matched donor. The patient's body must be rid of all tumor cells which involves the use of cytotoxic chemicals leaving the patient hematopoietically deficient. A source of bone marrow sample is then engrafted after which it takes 3 to 4 weeks for engraftment to occur.
In contrast to bone marrow transplants, the present invention allows one to identify and purify CD34-Lin- or CD34-CD38-Lin- cells from a suitable source such as bone marrow, cord blood or peripheral blood. These cells can then be enriched ex vivo and transplanted or infused back into a patient missing or deficient in a cell population. The cells may also be treated genetically or chemically prior to transplantation back into the patient. The procedure for reinfusion of the stem cells is less hannful to a patient than the reintroduction of bone marrow and requires a substantially smaller volume of cells than bone marrow transplants. It is understood by those skilled in the art that the cells of the present invention can be differentiated into various types of mature cells which may be used for transplantation.
Peripheral blood transplantation can also be used to isolate and provide back an enriched culture of CD34-Lin- or CD34-CD38-Lin- cells.
The invention provides a therapeutic composition comprising CD34- Lin- human hematopoietic stem cells. The invention also provides a therapeutic composition comprising CD34-CD38-Lin- human hematopoietic stem cells. Such compositions can be used to treat hematopoietic disorders such as malignancies (i.e. leukemia), immune disorders and diseases resulting from a failure or a dysfunction of normal blood cell production or maturation. Diseases may include but are not restricted to congenital disorders, severe combined immunodeficiency, Wiskott-Aldrich syndrome, Fanconi's anemia, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle
cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, megakaryoblastic leukemia, hematologic melanomas, lymphoma, multiple myeloma, myelodysplastic syndromes, carcinomas, neuroblastomas, arthritis and neurological genetic diseases (e.g. Gaucher Disease). It is understood by those skilled in the art that the compositions of the present invention may comprises substantially pure populations of CD34- Lin- human hematopoietic stem cells or CD34-CD38-Lin- human hematopoietic stem cells. The compositions may also comprise enriched cultures of CD34- Lin- or CD34-CD38-Lin- cells. Whether substantially pure or enriched, the compositions of the present invention may additionally comprise cells selected from the group consisting of CD34+ cells, Thy-1 cells, CD4+ cells, CD56+ cells, CD33+ cells, CD9+ cells, CD11+ cells, CD41+ cells, CD45 cells and mixtures thereof. The type of composition made depends on the end use. For example, for the treatment of leukemia it is desired to provide a composition comprising substantially homogenous populations of CD34-Lin- or CD34-
CD38-Lin- cells whereas for a standard stem cell transplant for other cancers or autoimmune diseases, the composition may comprise a mixture of CD34-Lin- or CD34-CD38-Lin- cells together with CD34+ cells.
It is also possible to utilize as therapeutic compositions substantially enriched populations of cells characterized phenotypically as CD34-Lin- or CD34-CD38-Lin- but which also may be further phenotypically characterized by the presence or absence of other antigenic markers.
It is also within the scope of the present invention to produce a composition comprising CD34-Lin- or CD34-CD38-Lin- cells to which infection fighting cells (B lymphocytes, T lymphocytes and their precursors) blood clotting cells (platelets), or any of the myeloid lineage cells (erythrocytes, granulocytes, macrophages, monocytes, basophils, eosinophils and their precursors) may be added to provide a "specialized" composition specific for a particular disease. It is also understood by those skilled in the art that various
pharmaceutical agents may be added to the compositions of the invention in order to treat specific disease states. For example, such pharmaceutical agents may include antibiotics, chemotherapeutic agents, cytokines, etc.
The stem cells of the present invention can be used to fight against both disease and infection. Cell populations to be transplanted can be screened and treated for infections such as viral (e.g. AIDS, herpes, hepatitis, etc.,), bacterial (e.g. staphylococcus, streptococcus, etc.,) and fungal in vitro. A sample of a patient's blood or bone marrow containing the infected cells can be purged of infection and the stem cells isolated and enriched ex vivo. In order to destroy the bacteria or virus which may affect such cells, the cultured cells may be treated with a suitable antiviral agent or antibacterial agent. Alternatively, the isolated cells can be individually screened to select for uninfected cells and the resulting population enriched. Prior to the implantation of the treated or untreated selected uninfected cells, the patient to receive such transplant is treated with a suitable chemical agent, drug or radiation treatment to eliminate all infected cells. The enriched sample of stem cells can then be transplanted into the patient. If desired, prior to transplantation into the patient, other cell types may be added to the culture of stem cells depending on the disease condition to be treated. For example, in the case of AIDS, a fresh supply of uninfected T-cells may also be added to the enriched culture of CD34-Lin- or CD34-CD38-Lin- cells.
In another embodiment, the CD34-Lin- or CD34-CD38-Lin- cells may be used as a method of gene therapy. The CD34-Lin- or CD34-CD38-Lin- cells may be isolated and enriched in in vitro culture where a desired genetic sequence can be inserted into the cells prior to their reintroduction into a patient. The genetic element introduced can simply be one to correct a defect in the cells themselves or to target a specific recombinant gene sequence to a specific area of the patient. Examples of diseases which may be treated with genetically altered stem cells of the present invention include but are not
restricted to hemophilia A, thalassemia, sickle-cell anemia, SCID and Gaucher's disease.
Methods of gene therapy are well known by those skilled in the art. Briefly, a sample of CD34-Lin- or CD34-CD38-Lin- cells are isolated from a source and cultured according to the method of the present invention. The cell culture is maintained under suitable conditions and the cells are subjected to techniques for the introduction and stable incorporation of a desired genetic sequence into the cells. Such introduction techniques may include transfection (calcium-mediated or microsome-mediated transfection), cell fusion, electroporation, microinjection or infection using recombinant vaccinia or retrovirus vectors. The cells which acquire the selected genetic sequence are then screened for, and reintroduced into a patient. Alternatively, the identifed cells may be further cultured to allow the cells to enrich and/or further differentiate to another cell type prior to being reintroduced into a patient. The cells of the present invention may be trans fected with a selected
DNA sequence encoding for a therapeutic agent such as an antibiotic, anticancer agents, peptides, cytotoxic compounds and antisense RNA. Alternatively, the cells may be transfected with an antigenic or immunogenic product which creates an immune response in a patient and reintroduction. In this manner, such cells would produce a vaccine like effect.
In a further embodiment of the invention, the cells of the present invention can be used for fetal genetic testing. The stem cells may be isolated from samples of peripheral blood taken from a pregnant woman which contain some fetal cells. Isolated fetal cells may be cultured and the stem cells isolated and tested for genetic abnormalities.
In still a further embodiment of the present invention, the stem cells of the present invention may be isolated and cultured in vitro and treated with specific factors and/or cytokines in order to produce a specific cell lineage such as immune cells, granulocytic, megakaryocytic, etc. which carry out a
specific function. Such specialized cells may be generated in large numbers and transplanted back into patients in order to treat them of a disease such as for example an autoimmune disease or one of the diseases listed supra.
Examples
The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.
Methods of synthetic chemistry, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well .known to those skilled in the art.
Example 1 - Analysis of CD34-Lin- cells found in human hematopoietic tissue Mononuclear cells were isolated from various human hematopoietic cell sources and stained with monoclonal antibodies for CD2, CD3, CD4, CD7, CD13, CD14, CD15, CD16, CD19, CD20, and glycophorin conjugated to FITC, CD38 conjugated to PE and CD34 conjugated to Cy-5 . Cells gated Rl did not express lineage associated markers (Lin-) and were further analyzed for the expression of CD34 and CD38.
Identification of CD34- cells with no lineage markers in human hematopoietic tissues
To determine whether CD34- cells that do not express lineage markers exist in human hematopoietic tissues, human cord blood cells were first depleted of mononuclear cells that express 15 different lineage-specific antigens from human cord blood. This Lin- population was 99% pure (data not shown). The Lin- cells were then stained with the most widely used CD34 class III monoclonal antibody conjugated to FITC. Flow cytometric analysis showed two distinct populations of CD34+ and CD34- cells (Fig 1A panel 1). The
CD34- cells (gated Rl, Fig. 1A, I) were collected by flow sorting and reanalysis demonstrated their high purity (99%; Fig. 1 A, II). To confirm that these cells did not express any surface CD34 antigen, the sorted cells were re-stained with two other CD34 Class I and II antibodies that recognize different epitopes of the CD34 molecule (Fig. 1 A, III and IN). No CD34+ cells were detected, attesting to the high purity and lack of CD34 cell surface expression of this CD34-Lin- population.
To exclude the possibility that CD34 protein was produced in the CD34- Lin- cells but not transported to the cell surface, cytospins of purified CD34- Lin- cells were permeabilized, stained with CD34 monoclonal antibodies conjugated to FITC and counter stained with DAPI (Fig. IB). No CD34-FITC signal was detected in the CD34-Lin- cells. The specificity of the procedure was shown by the detection of cell surface and intracellular expression of CD34 on a population of purified CD34+Lin- cells under similar conditions. Background fluorescence was indicated by staining cells with IgG conjugated to FITC as isotype control (Fig. IB). These results indicate that a population of Lin- cells exist in human cord blood that does not produce intracellular or cell surface CD34.
Heterogeneity within human CD34+Lin- cells is well documented and further subdivision for the most primitive cells is typically based on the cell surface markers CD38, c-kit, Thy-1 and HLA-DR. The expression of these markers on both the CD34+Lin- and CD34-Lin- cells was compared (Fig. IC). CD34-Lin- cells displayed a bi-modal distribution of CD38, clearly dividing the population into two fractions in contrast to the high proportion of CD34+Lin- cells that express CD38 (Fig. IC). Cell surface expression of c-kit was similar between that two populations, while the CD34-Lin- cells are almost exclusively Thy-1- and HLA-DR- (Fig. IC). Both the absence of HLA-DR expression and the presence of Thy- 1 have been proposed to define more primitive subfractions within the CD34+Lin- population. Therefore, the CD34-Lin-
population derived from cord blood is a distinct population which differs not only in CD34 expression from primitive CD34+Lin- cells but also in phenotypic heterogeneity based on additional markers associated with stem cells.
Example 2- Cell Immunostaining
Cord blood cells purified by flow cytometry as done previously (11, 12) were cytospun onto slides, permeabilized, and incubated in a BSA solution. The results are shown in Figure IB. (Column I) CD34+CD38-Lin- cells were stained with isotype control antibody conjugated to FITC (Becton Dickinson) and countered stained with DNA binding DAPI as a control for non-specific background flourescence. (Column II) CD34+CD38-Lin- cells and (Column III) CD34-Lin- cells were stained with CD34 monoclonal antibodies followed by DAPI counter stain. All slides were examined using a fluorescent microscope utilizing the appropriate filters for DAPI to detect the nucleus of cells and FITC for the presence of CD34 protein.
Both CD34-Lin- and CD34+Lin- purified cells were stained with monoclonal antibodies conjugated to fluorochromes for CD38 (Becton Dickinson, BD), c-kit (BD), Thy-1 (Coulter) and HLA-DR (BD). Stained populations were then washed and analyzed using standard flow cytometric techniques (J. Exp Med, PNAS) followed by the display of histograms using the Cell Quest software program (BD) (n=3).
Example 3 - Cell Engraftment Purified cell populations at the indicated dose were transplanted by tail vein injection into sublethally irradiated mice (375 cGy using a 137Cs g- irradiator) according to a standard protocol as previously described (16, 17). Mice were sacrificed 8 to 12 weeks post transplant and the bone marrow from the femurs, tibiae and iliac crests of each mouse were flushed into IMDM
containing 10% FCS. Mouse bone marrow was analyzed using FACS analysis and by southern analysis using genomic DNA extracted by standard protocols in which the level of human cell engraftment was determined by comparing the characteristic 2.7 kb band with those of huma mouse DNA mixtures as controls (limit of detection 0.05% human DNA) (16, 17). The results are shown in Figures 2 and 7.
Example 4 - Determination of Hematopoietic Progenitor Activity of CD34-Lin. CD34+CD38-Lin- and CD34-CD38+Lin- Highly purified cells were plated in clonogenic methlycellulose assays and seeded on MS-5 stroma in order to quantitate the CFC and LTC-IC content, respectively. Clonogenic capacity of CD34-Lin- cells was extremely low in comparison to CD34+CD38-Lin- cells (250 CFC vs. 8.9 CFC per 800 cells) (Table I). As many as 10,000 cells needed to be seeded on MS-5 stroma to detect a single LTC-IC within the CD34-Lin- cell fraction, while further purification demonstrated that detection of LTC-IC in the CD34-CD38-Lin- fraction required seeding of at least 2000 cells. By contrast, as few as 10 CD34+CD38-Lin- cells contain an LTC-IC. The CD34-CD38+Lin- cells were devoid of LTC-IC activity (limit of detection at 10,000 cells) but contained a much higher capacity to form CFC specifically committed to the erythroid lineage (Table I). The low efficiency of production of myeloid and erythroid committed progenitors, as well as the more primitive LTC-IC, is similar to observations made with murine CD34-Lin- cells in the same assay systems and suggest that functional similarities may exist between the CD34-Lin- cells from these two species (8, 10).
Example 5 - Multilineage Differentiation of Human CD34-Lin- cells in NOD/SCID mice after ex vivo Culture
A representative mouse was transplanted with 50,000 expanded CD34- Lin- cord blood cells after 2 days of ex-vivo culture in the presence of SF medium supplemented with 5% FCS. Mouse bone marrow was extracted 10 weeks after transplant and analyzed by multiparameter flow cytometry (11, 12). The results are shown in Figure 8.
CD34- Cell Culture with Growth Factors
CD34-Lin- cells were incubated in 50 ml of SF condition consisting of IMDM supplemented with 1% BSA (Stem Cell Technologies), 5 mg/ml of human insulin (Humulin R from Eli Lilly and Co.), 100 mg/ml of human transferrin (Gibco, BRL), 10 mg/ml of low density lipoproteins (Sigma Chemical Co.), 10-4 M Beta-mercaptoethanol and growth factors (GF). GF cocktail was used at final concentrations of 300 ng/ml of SCF (Amgen) and Flt- 3 (Immunex), 50 ng/ml of G-CSF (Amgen), 10 ng/ml of IL-3 (Amgen) and IL- 6 (Amgen). 25% of condition media obtained from a fresh umbilical vein endothelial cell culture in a low percentage of serum ( 10%) and passaged four times, was added in some wells. Cells were cultured in flat bottomed suspension wells of 96-well plates (Nunc), incubated for 2 and 4 days at 37oC and 5% C02 and 50 ml of fresh GF cocktail was added to each well every other day.
Example 6 - Effect of ex vivo culture on the number of clonogenic progenitors present in the CD34-Lin-. CD34-CD38-Lin- and CD34-CD38+Lin- cell fractions An aliquot of 800 to 2, 500 CD34-Lin-, CD34-CD38-Lin- or CD34-
CD38+Lin- cells were plated in clonogenic progenitor assays under standard conditions at the initiation of ex vivo cultures (day 0). Cells present after 4 days of culture in the presence of SF or SF supplemented with 5% FCS or 25% of HUVEC-CM were plated in the same conditions. The number of CFC/800
input cells were estimated (mean ] SEM ; n=number of experiment). The results are seen in Table II.
Example 7 - The effect of liquid culture on the development and potential differentiation of CD34-CD38-Lin- cells
Individual wells were analyzed by flow cytometry after 2 and 4 days of culture in various conditions (Fig. 6). CD34-CD38-Lin- cells seeded in SF media began to express CD34 which could be enhanced with the addition of serum (Fig. 6). In contrast, the majority of cells obtained after 2 or 4 days of culture in the presence of 25% HUNEC (human umbilical vein endothelial cell) conditioned medium still maintained the same phenotype. The acquisition of CD34 demonstrates the differentiation capacity of CD34-CD38-Lin- cells in- vitro. The production of CD34+CD38- cells suggests that CD34-CD38-Lin- cells precede CD34+CD38- population in the hierarchy of human hematopoiesis.
Example 8- Cytokine stimulation of CD34-CD38-Lin- Repopulating Activity
To evaluate the repopulating activity of CD34-Lin- and more highly purified CD34-CD38-Lin- cell fractions after ex vivo culture, cultured cells were injected into ΝOD/SCID mice and the level of human engraftment evaluated after 8 to 10 weeks. Purified cell fractions from 44 CB and 3 BM samples cultured for 2 and 4 days in SF, SF supplemented with 5% FCS or 25% HUVEC-CM were transplanted at various doses into 144 recipient ΝOD/SCID mice and the level of human cell engraftment was determined (Figure 7B). A total of 15 of 35 mice were engrafted following transplantation with CD34-Lin- cells that had been cultured for 4 days in SF or 5% FCS at cell doses below the calculated frequency of CD34-SRC. For example, 13 of 29 mice were engrafted following transplantation of 50,000 to as few as 4,000 cultured CD34-Lin- cells. By contrast, only 1 of 7 mice were engrafted when 100,000
uncultured CD34-Lin- cells were transplanted (Figure 2). Similarly, a higher proportion of mice (33%) transplanted with cultured CD34-CD38-Lin- cells were engrafted (Figure 7B) compared to mice transplanted with similar doses of uncultured CD34-CD38-Lin- (Figure 7B). Quantitative analysis using Poisson statistics indicated a frequency of 1 CD-SRC in 38,000 cultured CD34- CD38-Lin- cells (range 1/22,000 to 1/71,000). It was not possible to calculate the frequency of CD34-SRC in uncultured CD34-CD38-Lin- cells (Figure 7 A) because there was infrequent engraftment despite injection of as many as 50,000 cells. This result indicates that the actual stem cell frequency of freshly isolated cells must be much lower compared to cultured cells. The human lineage distribution in mice transplanted with expanded CD34-Lin- and CD34- CD38-Lin- cells is similar to that with unstimulated purified CD34-Lin- cells (Figure 8). In addition, the inability of cultured CD34-CD38+Lin- cells to engraft mice confirms the absense of repopulating cells within this fraction. It was evident that culture conditions, especially HUVEC-CM, induce an increase in the number of CD34-SRC in the absence of cell proliferation.
The bone marrow of engrafted mice was analyzed by multiparameter flow cytometry to determine whether cultured CD34-Lin- repopulating cells possessed the same in vivo proliferative and differentiative capacity as uncultured cells. A representative analysis of the bone marrow of a NOD/SCID mouse transplanted with an initial population of 40,000 CD34-Lin- cells after 4 days of culture is shown in Figure 8. The bone marrow of this mouse contained 7% human cells as detected by expression of CD45, a human specific pan- leukocyte marker (Fig. 8). Both B and T-lymphoid cells were present in the murine bone marrow as shown by staining for CD 19, CD20 and CD4, CD3 antigens (Fig. 8D-F). The presence of CD33+, CD14+, CD15+ and CD13+ cells indicated the differentiation potential of CD38-CD38-Lin- cells to the myeloid lineages (Fig. 8G-H). The engraftment pattern of mice transplanted with expanded CD34-CD38-Lin- cells is similar to that observed with
unstimulated purified CD34-Lin- cells. The presence of human T-cells is a unique feature of CD34-Lin- engraftment, since T-cells have not been detected in mice transplanted with purified CD34+CD38-Lin- cells either before or after ex vivo culture.
Example 9 - Testing of Whether CD34-SRC are Biologically Distinct from CD34+SRC.
To test whether the CD34+SRC are lost if CD34+CD38-Lin- or CD34+Lin- cells are cultured in the presence of serum, CD34+CD38-Lin- and CD34-Lin- cells from the same human CB sample were cultured for 4 days under the dame serum containing conditions. In a representative experiment, 3 out of 6 mice were engrafted following transplantation with cultured CD34- Lin- cells (Figure 9). In contrast, 5,000 and 10,000 CD34+CD38-Lin- cells, containing 10-20 CD34+SRC, cultured under the same conditions were unable to engraft NOD/SCID mice. These results provide independent confirmation that the repopulating cells derived from the CD34-Lin- subtraction are biologically distinct from those derived from CD34+CD38-Lin- cells.
For the DNA analysis shown in Figure 9, NOD/SCID mice were transplanted with CD34-Lin- or CD34+CD38-Lin- cells purified from the same cord blood sample and cultured in the presence of 5% FCS. A southern blot was performed using standard techniques and was hybridized with a human chromosome 17-specific α-satellite probe.
The present invention is not limited to the features of the embodiments described herein, but includes all variations and modifications within the scope of the claims.
Table 1
Hematopoietic Progenitor Activity of CD34-Lin-. CD34-CD38-Lin- and CD34-CD38+Lin-
Phenotype of purified CFC/800 cells Frequency of population LTC-IC
CD34-Lin- 8.9+3 <l/10,000 (n=2) exp #l (n=4) 5,501±1640(n=2) exp#2
CD34-Lin-CD38- 2.7±2 <l/2,000 (n=36) (n=4)
CD34-Lin-CD38+ 77+31 < 1/10,000 (n=10) (n=4)
CD34+CD38- 250±46 >1/10 (n=4) (n= )
Table 2
Effect of ex vivo culture on the number of clonogenic progenitors present in the CD34-Lin-, CD34-CD38-Lin- and CD34-CD38+Lin- cell fractions.
Phenotype of purified Day Medium Number l~?l population
CD34-Lin- 8.9 ±3 Serum Free 10 ±0.9 (n=4)
(n=4) 5% Serum 76 ±21 (n=2)
CD34-Lin-CD38- 2.7± 2 5% Serum 6.4 ±4.5 (n=7)
(n=36) Serum Free 1.2 ±l (n=9)
25% HUVEC0.5% ±0.5 (n=7)
CD34-Lin-CD38+ 77 ±31 Serum Free 20 ±10 (n=4)
(n=10) 5% Serum 134± 41 (n=4)
*CFC/800 Input Cells
Claims
1. A substantially homogeneous population of human hematopoietic stem cells which are CD34-Lin-.
2. A substantially homogeneous population of human hematopoietic stem cells which are CD34-CD38-Lin-.
3. The population of claim 1 or 2, wherein said stem cells are further characterized by the presence or absence of other antigenic phenotypic markers.
4. A therapeutic composition comprising an effective amount of CD34- Lin- human hematopoietic stem cells and a pharmaceutically acceptable carrier.
5. A therapeutic composition comprising an effective amount of CD34- CD38-Lin- human hematopoietic stem cells and a pharmaceutically acceptable carrier.
6. The composition of claims 4 or 5, wherein said composition additionally comprises cells selected from the group consisting of CD34+ cells, Thy-1 cells, CD4+cells, CD56+ cells, CD33+ cells, CD9+ cells, CD 11 + cells, CD41 + cells, CD45+ cells and mixtures thereof.
7. The composition of claim 6, wherein said composition additionally comprises cells selected from the group consisting of B lymphocytes, T lymphocytes, platelets and myeloid lineage cells.
8. The composition of claim 6, wherein said composition additionally comprises at least one pharmaceutical agent.
9. A method for obtaining a substantially enriched population of CD34- Lin- human hematopoietic cells comprising the steps of:
- removing mononuclear cells expressing some lineage-specific antigens from a sample of hematopoietic cells; - combining the resultant hematopoietic cells with labeled antibodies to which bind specifically to CD34+; and
- isolating the unbound CD34-Lin- cells.
10. The method of claim 9, wherein said sample of hematopoietic cells is selected from the group consisting of fetal cells, bone marrow, cord blood and peripheral blood.
11. A method for reconstituting hematopoiesis in an immunocompromised subject, the method comprising administering to a subject a composition comprising an enriched population of CD34- Lin- stem cells.
12. A method for introducing CD34-Lin- stem cells in a mammal, said method comprising the steps of:
- providing an enriched population of CD34-Lin- stem cells; and - introducing said stem cells into said mammal.
13. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells are characterized as CD34-CD38-Lin-.
14. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells are isolated from bone marrow, cord blood, fetal blood, peripheral blood or bone marrow.
15. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells are genetically altered in vitro prior to introducing said stem cells into said mammal.
16. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells are pharmaceutically or chemically treated in vitro prior to introducing said stem cells into said mammal.
17. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells are differentiated into CD34+ cells prior to introducing said stem cells into said mammal.
18. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells is introduced into a mammal having a disorder selected from the group consisting of leukemia, infection, immune disorders, Wiskott-Aldrich syndrome, Fanconi's anemia, severe combined immunodeficiency, congenital disorders, congenital red cell aplasia, lysosomal storage disease, thalassemia major, sickle cell anemia, aplastic anemia, acute lymphoblastic leukemia, acute myelogenous leukemia, megakaryoblastic leukemia, hematologic melanomas, lymphoma, multiple myeoloma, myolodysplastic syndromes, carcinomas, neuroblastomas, arthritis and neurological genetic disease.
19. The method of claim 12, wherein said enriched population of CD34-Lin- stem cells is introduced into a mammal in order to replace a deficient cell type.
20. A method of treating a hematopoietic disorder in a subject, comprising: - providing an enriched population of human CD34-CD38-Lin- stem cells; administering said stem cells to the subject in need of treatment.
21. The method of claim 20, wherein the population of stem cells is cultured in vitro before administering the cells to the subject.
22. A method for the production of CD34+ stem cells, said method comprising:
- providing an enriched population of human CD34-CD38-Lin- stem cells;
- culturing said stem cells in vitro under suitable conditions for a time sufficient to allow said cells to differentiate into CD34+ cells; and
- isolating CD34+ stem cells.
23. A method for expanding a population of CD34-Lin- stem cells, said method comprising the steps of: - isolating CD34-Lin- stem cells from suitable hematopoietic source;
- culturing said isolated cells in vitro for a time sufficient and under culture conditions to result in the expansion of said cells.
24. The method of claim 23, wherein certain agents are added to said cell culture to allow said cells to differentiate into a mature cell type.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2307624 CA2307624A1 (en) | 1997-10-31 | 1998-10-30 | Hematopoietic stem cells |
| AU97320/98A AU9732098A (en) | 1997-10-31 | 1998-10-30 | Hematopoietic stem cells |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002219869A CA2219869A1 (en) | 1997-10-31 | 1997-10-31 | Human cd-34 hematopoietic stem cells |
| CA2,219,869 | 1997-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999023205A1 true WO1999023205A1 (en) | 1999-05-14 |
Family
ID=4161713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1998/001012 WO1999023205A1 (en) | 1997-10-31 | 1998-10-30 | Hematopoietic stem cells |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU9732098A (en) |
| CA (2) | CA2219869A1 (en) |
| WO (1) | WO1999023205A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002039109A3 (en) * | 2000-11-07 | 2003-05-01 | British Columbia Cancer Agency | Method for the detection of human hematopoietic short term repopulating cells |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| WO2005056026A1 (en) * | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
| US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
| EP2292734A1 (en) | 2001-12-07 | 2011-03-09 | Geron Corporation | Hematopoietic cells from human embryonic stem cells |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
| CN110082515A (en) * | 2012-12-21 | 2019-08-02 | 干细胞生物科技公司 | Utilize the method for stem cell data assessment Behavioral effect |
| US10617721B2 (en) | 2013-10-24 | 2020-04-14 | Ospedale San Raffaele S.R.L. | Methods for genetic modification of stem cells |
| CN112585261A (en) * | 2018-06-07 | 2021-03-30 | 布里格姆妇女医院 | Method for producing hematopoietic stem cells |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039489A1 (en) * | 1995-06-06 | 1996-12-12 | Whitehead Institute For Biomedical Research | Isolation of mammalian hematopoietic stem cells |
-
1997
- 1997-10-31 CA CA002219869A patent/CA2219869A1/en not_active Abandoned
-
1998
- 1998-10-30 CA CA 2307624 patent/CA2307624A1/en not_active Abandoned
- 1998-10-30 WO PCT/CA1998/001012 patent/WO1999023205A1/en active Application Filing
- 1998-10-30 AU AU97320/98A patent/AU9732098A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039489A1 (en) * | 1995-06-06 | 1996-12-12 | Whitehead Institute For Biomedical Research | Isolation of mammalian hematopoietic stem cells |
Non-Patent Citations (5)
| Title |
|---|
| BHATIA M ET AL: "A newly discovered class of human hematopoietic cells with SCID-repopulating activity [see comments].", NATURE MEDICINE, (1998 SEP) 4 (9) 1038-45, XP002097293 * |
| BHATIA M ET AL: "Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 MAY 13) 94 (10) 5320-5, XP002097291 * |
| BHATIA, MICKIE ET AL: "Identification of a novel CD34 negative population of primitive human hematopoietic cells capable of repopulating NOD/SCID mice.", BLOOD, (NOV. 15, 1997) VOL. 90, NO. 10 SUPPL. 1 PART 1, PP. 258A. MEETING INFO.: 39TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY SAN DIEGO, CALIFORNIA, USA DECEMBER 5-9, 1997 THE AMERICAN SOCIETY OF HEMATOLOGY, XP002097292 * |
| GAN O I ET AL: "Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells.", BLOOD, (1997 JUL 15) 90 (2) 641-50, XP002097290 * |
| OSAWA M ET AL: "Long-term lymphohematopoietic reconstitution by a single CD34 -low/negative hematopoietic stem cell.", SCIENCE, (1996 JUL 12) 273 (5272) 242-5, XP002097289 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| US7223549B2 (en) | 2000-06-22 | 2007-05-29 | Andrew N. Marakovskiy | Compositions for identification and isolation of stem cells |
| WO2002039109A3 (en) * | 2000-11-07 | 2003-05-01 | British Columbia Cancer Agency | Method for the detection of human hematopoietic short term repopulating cells |
| EP2292734A1 (en) | 2001-12-07 | 2011-03-09 | Geron Corporation | Hematopoietic cells from human embryonic stem cells |
| US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
| JP2007513188A (en) * | 2003-12-04 | 2007-05-24 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Compositions and methods for the treatment of lysosomal storage diseases |
| WO2005056026A1 (en) * | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
| US8580249B2 (en) | 2003-12-04 | 2013-11-12 | Regents Of The University Of Minnesota | Cell therapy for the treatment of lysosomal storage disorders |
| US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
| CN110082515A (en) * | 2012-12-21 | 2019-08-02 | 干细胞生物科技公司 | Utilize the method for stem cell data assessment Behavioral effect |
| US10617721B2 (en) | 2013-10-24 | 2020-04-14 | Ospedale San Raffaele S.R.L. | Methods for genetic modification of stem cells |
| CN112585261A (en) * | 2018-06-07 | 2021-03-30 | 布里格姆妇女医院 | Method for producing hematopoietic stem cells |
| US12286643B2 (en) | 2018-06-07 | 2025-04-29 | The Brigham And Women's Hospital, Inc. | Methods for generating hematopoietic stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2307624A1 (en) | 1999-05-14 |
| AU9732098A (en) | 1999-05-24 |
| CA2219869A1 (en) | 1999-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klöß et al. | Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells | |
| US5665557A (en) | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof | |
| US7927785B2 (en) | Methods for in vitro expansion of hematopoietic stem cells | |
| CA2236263C (en) | Methods for use of mpl ligands with primitive human stem cells | |
| JP2002516085A (en) | Compositions and uses that affect hematopoietic stem cell populations in mammals | |
| CN102781449A (en) | Methods for enhancing natural killer cell proliferation and activity | |
| AU2006321172B2 (en) | Methods of improving stem cell homing and engraftment | |
| Chute et al. | A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures | |
| TW202003837A (en) | Group of CD3-negative cells expressing chemokine receptors and cell-adhesive molecules, and their uses and methods of manufacture | |
| WO1999023205A1 (en) | Hematopoietic stem cells | |
| JPH06508528A (en) | In vitro derived human neutrophil precursor cells | |
| JPH10136978A (en) | Culture of hematopoietic stem cell | |
| AU782937B2 (en) | Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same | |
| Rowley et al. | Hematopoietic precursors resistant to treatment with 4-hydroperoxycyclophosphamide: requirement for an interaction with marrow stroma in addition to hematopoietic growth factors for maximal generation of colony-forming activity | |
| US20020098521A1 (en) | Method and marker for the isolation of human multipotent hematopoietic stem cells | |
| Holyoake et al. | The CD34 antigen: potential clinical advantages of CD34 selection | |
| Vavrova et al. | Ex vivo expansion CD34+/AC133+-selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy | |
| Greinix et al. | Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules | |
| TWI876354B (en) | A group of CD3 negative cells expressing a tropism factor receptor and a cell adhesion molecule, and its use and its production method | |
| EP1673445B1 (en) | Blood products from mesenchymal stem cells | |
| WO1999000486A1 (en) | Compositions and methods for inducing the development and differentiation of hemopoietic stem cells | |
| Roberts et al. | Impact of cell culture technology on transfusion medicine | |
| Greinix et al. | Specific growth inhibition of primitive hematopoietic progenitor cells | |
| Su | Ex vivo expansion of hematopoietic stem and progenitor cells from umbilical cord blood: Cytokine combinations, platelet-derived growth factor and stromal cell support |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 2307624 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09530504 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase |